Skip to main content

Amylyx Pharmaceuticals, Inc.

AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001658551

In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.

13F holders, Q4 2024

Institutional positions in Amylyx Pharmaceuticals, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
122
+13 vs. Q3 2024
Shares held
49.8M
+6.68M (+15.5%) vs. Q3 2024
Total value
$188.3M
+$48.6M (+34.8%) vs. Q3 2024
New holders
33
35 more added
Sold out
20
40 more reduced

1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2024: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting AMLX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2024: 122 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 0 institutionsQ4 2021: 0 institutionsQ1 2022: 72 institutionsQ2 2022: 78 institutionsQ3 2022: 95 institutionsQ4 2022: 133 institutionsQ1 2023: 147 institutionsQ2 2023: 154 institutionsQ3 2023: 170 institutionsQ4 2023: 178 institutionsQ1 2024: 143 institutionsQ2 2024: 119 institutionsQ3 2024: 110 institutionsQ4 2024: 122 institutionsQ1 2025: 136 institutionsQ2 2025: 131 institutionsQ3 2025: 169 institutionsQ4 2025: 180 institutionsQ1 2026: 171 institutionsQ2 2026: 206 institutions
Value heldQ4 2024: $188.3M
Q1 2021: $0Q2 2021: $0Q3 2021: $0Q4 2021: $0Q1 2022: $299.9MQ2 2022: $512.9MQ3 2022: $1.05BQ4 2022: $1.79BQ1 2023: $1.51BQ2 2023: $1.18BQ3 2023: $1.08BQ4 2023: $887.4MQ1 2024: $141.5MQ2 2024: $82.9MQ3 2024: $140.8MQ4 2024: $188.3MQ1 2025: $261.6MQ2 2025: $523.6MQ3 2025: $1.49BQ4 2025: $1.36BQ1 2026: $1.59BQ2 2026: $2.07B
Institutions holding AMLX and their total value by quarter
QuarterHoldersValue
Q2 2026206$2.07B
Q1 2026171$1.59B
Q4 2025180$1.36B
Q3 2025169$1.49B
Q2 2025131$523.6M
Q1 2025136$261.6M
Q4 2024122$188.3M
Q3 2024110$140.8M
Q2 2024119$82.9M
Q1 2024143$141.5M
Q4 2023178$887.4M
Q3 2023170$1.08B
Q2 2023154$1.18B
Q1 2023147$1.51B
Q4 2022133$1.79B
Q3 202295$1.05B
Q2 202278$512.9M
Q1 202272$299.9M
Q4 20210$0
Q3 20210$0
Q2 20210$0
Q1 20210$0

Institutions, Q4 2024

Shares, value and share of portfolio for each institution holding Amylyx Pharmaceuticals, Inc.; share changes are against Q3 2024.

Institutions holding AMLX in Q4 2024
InstitutionSharesValue% of portfolioChange in sharesAction
Acadian Asset Management LLC611,926$2.31M0.01%−1,158,271−65.4%Reduced
UBS Group AG643,524$2.43M0.00%+414,448+180.9%Added
Two Sigma Investments, LP651,517$2.46M0.01%+284,280+77.4%Added
FMR LLC731,356$2.76M0.00%+510,355+230.9%Added
Jane Street Group, LLC765,475$2.89M0.00%+421,302+122.4%Added
Qube Research & Technologies Ltd780,566$2.95M0.00%+596,672+324.5%Added
Alyeska Investment Group, L.P.823,420$3.11M0.01%−1,200,000−59.3%Reduced
Susquehanna International Group, LLP868,382$3.28M0.00%+462,225+113.8%Added
Saturn V Capital Management LLC889,073$3.36M1.32%+889,073New
Connor, Clark & Lunn Investment Management Ltd.1,263,353$4.78M0.02%+382,608+43.4%Added
Nantahala Capital Management, LLC1,452,153$5.49M0.38%+47,589+3.4%Added
Standard Life Aberdeen plc1,722,805$6.51M0.01%−249,437−12.6%Reduced
Boxer Capital Management, LLC1,750,000$6.62M0.56%+1,750,000New
Goldman Sachs Group Inc1,859,896$7.03M0.00%+246,033+15.2%Added
683 Capital Management, LLC1,930,000$7.30M0.72%−70,000−3.5%Reduced
Citadel Advisors LLC1,970,704$7.45M0.01%+71,144+3.7%Added
Almitas Capital LLC2,032,370$7.68M1.69%+43,807+2.2%Added
BlackRock, Inc.2,278,934$8.61M0.00%−269,272−10.6%Reduced
Bank of America Corp2,426,263$9.17M0.00%+1,513,748+165.9%Added
Vanguard Group Inc2,692,489$10.2M0.00%−397,156−12.9%Reduced
TCG Crossover Management, LLC4,643,812$17.6M1.72%00.0%Unchanged
Perceptive Advisors LLC6,774,348$25.6M0.71%+4,648,699+218.7%Added
Farallon Capital Management, L.L.C.0$00.00%−1,150,221−100.0%Sold out
First Trust Advisors LP0$00.00%−221,626−100.0%Sold out
ADAR1 Capital Management, LLC0$00.00%−220,906−100.0%Sold out
Panagora Asset Management Inc0$00.00%−188,465−100.0%Sold out
Shay Capital LLC0$00.00%−117,328−100.0%Sold out
Algert Global LLC0$00.00%−106,219−100.0%Sold out
HRT Financial LP0$00.00%−81,291−100.0%Sold out
Graham Capital Management, L.P.0$00.00%−67,956−100.0%Sold out
Savant Capital, LLC0$00.00%−57,565−100.0%Sold out
Legacy Advisors, LLC0$00.00%−50,000−100.0%Sold out
Bank of New York Mellon Corp0$00.00%−23,679−100.0%Sold out
Premier Path Wealth Partners, LLC0$00.00%−20,265−100.0%Sold out
Aries Wealth Management0$00.00%−15,000−100.0%Sold out
Corton Capital Inc.0$00.00%−13,104−100.0%Sold out
Bayesian Capital Management, LP0$00.00%−10,700−100.0%Sold out
Atria Wealth Solutions, Inc.0$00.00%−10,000−100.0%Sold out
Catalyst Funds Management Pty Ltd0$00.00%−7,500−100.0%Sold out
nVerses Capital, LLC0$00.00%−2,100−100.0%Sold out
Ronald Blue Trust, Inc.0$00.00%−2,104−100.0%Sold out
Point72 Asset Management, L.P.0$00.00%−200−100.0%Sold out
Ghost Tree Capital, LLC––––Not filed